CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| 10106 | ETCTN | A phase I and randomized phase II study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in relapsed, refractory diffuse large-B cell lymphoma | Adult CIRB - Early Phase Emphasis | Completed |
| 9878 | ETCTN | A Phase 1/2 Trial of Erlotinib and Onalespib lactate in EGFR-Mutant Non-Small Cell Lung Cancer | Adult CIRB - Early Phase Emphasis | Completed |
| GOG-0218 | GOG | A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC #704865; IND #113912) Followed by Placebo; Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab; in Women With Newly Diagnosed; Previously Untreated; Stage III or IV; Epithelial Ovarian; Primary Peritoneal or Fallopian Tube Cancer | Adult CIRB - Late Phase Emphasis | Completed |
| C80405 | CALGB | A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab; or Cetuximab (C225); or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum | Adult CIRB - Late Phase Emphasis | Completed |
| RTOG-0521 | RTOG | A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs. AS and 3DCRT/IMRT followed by Chemotherapy with Docetaxel and Prednisone for Localized; High-Risk Prostate Cancer | Adult CIRB - Late Phase Emphasis | Completed |
| S0347 | SWOG | A Randomized Study of Weekly Vinorelbine (Navelbine) Alone or in Combination with Trastuzumab (Herceptin) (NSC-688097) for Patients with HER-2-Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane + Trastuzumab Combination Therapy - Phase III | Adult CIRB - Late Phase Emphasis | Completed |
| ADVL1221 | COG | A Phase II Study of Cixutumumab (IMC-A12; IND# 100947) in Combination with Temsirolimus (IND# 61010) in Pediatric Patients with Recurrent or Refractory Solid Tumors | Pediatric CIRB | Completed |
| ARET0332 | COG | A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Groupwide Phase III Study | Pediatric CIRB | Completed |
| E2212 | ECOG | A Randomized; Double-Blinded; Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver | Adult CIRB - Early Phase Emphasis | Completed |
| URCC-18004CD | NCORP-University of Rochester Cancer Center | Understanding the Impact of Drug Shortages on Oncology Care Delivery | Cancer Prevention and Control CIRB | Completed |